Toward rational management of patent ductus arteriosus: ductal disease staging and first line paracetamol
Toward rational management of patent ductus arteriosus: ductal disease staging and first line paracetamol
复制标题
DOI:
10.1080/14767058.2019.1702949
复制
发表时间:
2019-12-27
影响因子:
1.8
通讯作者:
Tan, Kenneth
中科院分区:
文献类型:
--
作者:
Sehgal, Arvind;Nitzan, Itamar;Tan, Kenneth
Aims: To study paracetamol (PCM) use as first line therapy for significant patent ductus arteriosus (sPDA) closure, stratified by echocardiography. Methods: In this retrospective observational study, a prepublished score comprising PDA size and velocity, PDA:left pulmonary artery ratio, diastolic flow in main and LPA, LA:Ao ratio and left ventricular:aortic ratio were included for shunt severity. Successful closure was defined a priori as closure or >= 50% reduction in score. Comparisons were made between infants with sPDA who were treated and not treated. Results: During November 2017-2018, 227 infants from 23 to 31(+6) weeks' gestational age (GA) were admitted; 50 (22%) infants were diagnosed with PDA, 32 treated with PCM, overall treatment rate of 32/227 (14%). Successful therapy was noted in 23/32 (72%) and was higher when treated at 26 weeks GA (62.5 versus 100%, p = .07) and BW >1000 g (65.4 versus 100%, p = .14). Univariate analysis noted statistical significance only for GA. Eighteen infants were managed conservatively. Treated infants had a lower GA and BW, higher composite ECHO score (14.4 +/- 0.5 versus 19 +/- 0.4, p < .001). Conclusions: Composite scoring helped reduce exposure, and focus more on infants with lower GA and BW with greater shunt severity.